EXHIBIT 1.2
AMENDMENT TO $25 MILLION SALES AGREEMENT
October 19, 2001
Cantor ▇▇▇▇▇▇▇▇▇▇ & Co.
▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇
Dear Sirs and Ladies:
Reference is made to that certain Sales Agreement dated June 12, 2001
between NeoTherapeutics, Inc. (the "Company") and Cantor ▇▇▇▇▇▇▇▇▇▇ & Co.
("CF&Co") with respect to the sale of up to $25 million aggregate sales price of
Common Stock, par value $.001 per share (the "Sales Agreement"). The parties
hereto agree to amend the Sales Agreement as follows:
1. Section 7(h) is hereby deleted and replaced with the following:
(h) The Company, whether or not the transactions contemplated
hereunder are consummated or this Agreement is terminated, will pay
all expenses incident to the performance of its obligations hereunder,
including, but not limited to, expenses relating to (i) the
preparation, printing and filing of the Registration Statement as
originally filed, of each Prospectus and of each amendment and
supplement thereto, (ii) the preparation, issuance and delivery of the
Shares, (iii) the fees and disbursements of the Company's counsel and
accountants, (iv) the qualification of the Shares under securities
laws in accordance with the provisions of Section 7(d) of this
Agreement, including filing fees and any reasonable fees or
disbursements of counsel for CF&Co in connection therewith, (v) the
printing and delivery to CF&Co of copies of the Prospectus and any
amendments or supplements thereto, and of this Agreement, (vi) the
fees and expenses incurred in connection with the listing or
qualification of the Shares for trading on the Nasdaq National Market
and (vii) filing fees, if any, of the Commission and the National
Association of Securities Dealers, Inc. In addition to any fees that
may be payable to CF&Co under this Agreement, the Company will
reimburse CF&Co all of its out-of-pocket expenses (including legal
fees and disbursements) incurred in connection with the negotiation
and preparation of this Agreement and the consummation of the
transactions contemplated hereby up to an aggregate maximum of
$60,000. In the event that this Agreement is terminated for any
reason, CF&Co shall be entitled to be reimbursed by the Company only
in respect of its actual accountable out-of-pocket expenses.
2. Schedule 1 shall be deleted and replaced with Schedule 1 attached
hereto.
Cantor ▇▇▇▇▇▇▇▇▇▇ & Co.
October 19, 2001
Page 2
Except as provided herein, all other provisions of the Sales Agreement will
remain in full force and effect.
Please indicate your agreement with the foregoing by signing where
indicated below and returning a signed copy to us, upon which this letter will
become a binding agreement between us.
Very truly yours,
NEOTHERAPEUTICS, INC.
By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇
---------------------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇
Title: Senior Vice President Finance,
Chief Financial Officer,
Secretary and Treasurer
Agreed and Accepted
as of October 19, 2001
CANTOR ▇▇▇▇▇▇▇▇▇▇ & CO.
By: /s/ ▇▇▇▇ ▇▇▇▇▇▇
------------------------------
Name: ▇▇▇▇ ▇▇▇▇▇▇
Title: President
SCHEDULE 1
COMPENSATION
1. The amount of any discount, commission or other compensation to be paid
by the Company to CF&Co for effecting sales of Placement Shares shall be as
follows:
COMMISSION DISCOUNT PROCEEDS
------------------- --------
4.00% $0 - $10,000,000
3.5% of proceeds on the next: $10,000,001 - $20,000,000
3.00% of proceeds on the next: $20,000,001 - $40,000,000
2.75% of proceeds on the next: $40,000,001 +
2. With respect to each accepted Placement Notice, the Company will issue
to CF&Co a five year warrant to purchase shares of Common Stock of the Company
in an amount equal to10% of the number of shares of Common Stock sold by the
Company pursuant to such Placement Notice. Each such warrant will have an
exercise price equal to 130% of the volume weighted average sale price of the
shares of Common Stock sold pursuant to the applicable Placement Notice, will be
dated as of the last Settlement Date (as defined in the Sales Agreement) for
sales of Common Stock made under the applicable Placement Notice and will
otherwise be in substantially the form attached hereto as Exhibit A to this
Schedule 1. Each such warrant shall be delivered to CF&Co within seven days
after the later of: (i) the last Settlement Date for sales of Common Stock made
under the applicable Placement Notice, or (ii) the date on which the Company
receives written notice from CF&Co that no further sales will be made pursuant
to such Placement Notice.
3. Registration Rights.
A. DEFINITIONS. For purposes of this Section 3:
(i) "Board" means the Board of Directors of the Company, as the
same shall be constituted from time to time.
(ii) "Exempt Registration" means a registration statement
relating to the sale of securities by the Company pursuant to a stock
option, stock purchase or similar benefit plan or an SEC Rule 145
transaction or any other registration statement that would not
customarily provide for the secondary sale of equity shares for cash.
(iii) "Form S-3" means such form under the Securities Act as in
effect on the date hereof or any successor form under the Securities
Act that is intended to be used as a short form for the registration
of distributions of secondary shares.
(iv) "Holder" means any person owning or having the right to
acquire Registrable Securities or any assignee thereof in accordance
with the provisions of this Agreement.
-1-
(v) "person" means any individual, corporation, partnership,
limited liability company, trust, business, association or government
or political subdivision thereof, governmental agency or other entity.
(vi) "register," "registered," and "registration" refer to a
registration effected by preparing and filing a registration statement
or similar document in compliance with the Securities Act and the
declaration or ordering of effectiveness of such registration
statement or document.
(vii) The term "Registrable Securities" means as of any given
date, shares of Common Stock issuable or issued upon exercise of
warrants issued to CF&Co pursuant to this Agreement which warrants are
or were issued as of a date not less than one year prior to such date;
provided, however, that the foregoing definition shall exclude in all
cases (x) any securities sold or transferred by a Holder in a
transaction in which such Holder's rights under this Section 3 are not
assigned, and (y) any securities that may be sold by the Holder
thereof pursuant to Rule 144 under the Securities Act.
(viii) "SEC" means the Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act.
(ix) "Securities Act" means the Securities Act of 1933, as
amended.
B. FORM S-3 REGISTRATION. In case the Company shall receive from any Holder
or Holders then holding not less than 100,000 Registrable Securities, including
Registrable Securities issuable upon the exercise of warrants then held by such
Holder or Holders, a written request or requests that the Company effect a
resale registration statement on Form S-3 and any related qualification or
compliance with respect to not less than 100,000 Registrable Securities held by
such Holder or Holders, the Company will:
(i) Promptly give written notice of the proposed registration,
and any related qualification or compliance, to all other Holders, if
any; and
(ii) As soon as practicable, effect such registration and all
such qualifications and compliances as may be so requested and as
would permit or facilitate the sale and distribution of all or such
portion of such Holder's or Holders' Registrable Securities as are
specified in such request, together with all or such portion of the
Registrable Securities of any other Holder or Holders joining in such
request as are specified in a written request given within 15 days
after receipt of such written notice from the Company; provided,
however, that the Company shall not be obligated to effect any such
registration, qualification or compliance, pursuant to this subsection
B: (w) if Form S-3 is not available for such offering by the Holders;
(x) if the Company shall furnish to the Holders a certificate signed
by the Chief Executive Officer of the Company stating that in the good
faith judgment of the Board of Directors of the Company, it would be
seriously detrimental to the Company and its shareholders for such
Form S-3 registration statement to be filed or declared effective at
such time, in which event the Company shall have the right to defer
the filing of the Form S-3 registration statement for a period of not
more
-2-
than 60 days after receipt of the request of the Holder or Holders
under this subsection B; provided, however, that the Company shall not
utilize this right more than once in any twelve month period; (y) if
the Company previously effected a registration on Form S-3 for any
Holders pursuant to this Subsection B which registration statement has
been declared effective and has remained effective for a period of at
least the lesser of (A) 90 days or (B) until the distribution
contemplated thereby shall have been completed; or (z) in any
particular jurisdiction in which the Company would be required to
qualify to do business or to execute a general consent to service of
process in effecting such registration, qualification or compliance.
(iii) Subject to the foregoing, the Company shall file a
registration statement covering the Registrable Securities and other
securities so requested to be registered as soon as practicable after,
and in any event within 45 days after (the "Filing Deadline"), receipt
of any request or requests of the Holders and use its commercially
reasonable efforts to cause such filed registration statement to
become effective by the Effectiveness Date. "Effectiveness Date" means
the 90th day following receipt by the Company of any request or
requests of their Holders.
(iv) No request pursuant to this Section 3B may be made after
August 30, 2006, and the Holders shall be entitled to only one (1)
registration pursuant to this Section 3B.
C. COMPANY REGISTRATION.
(i) Initiation. If the Company proposes to register (including for
this purpose a registration effected by the Company for stockholders other
than the Holders) any of its stock in connection with the public offering
of such securities solely for cash (other than an Exempt Registration), the
Company shall, at such time, promptly give each Holder notice of such
proposed registration. Upon the written request of each Holder given within
20 days after receipt by such Holder of the Company's notice, the Company
shall, subject to the provisions of the remainder of this Section C, cause
to be included in such registration statement all of the Registrable
Securities that each such Holder has requested to be registered.
(ii) Underwritten Offering. In connection with any offering involving
an underwriting of shares of the Company's capital stock, the Company shall
not be required under paragraph C(i) to include any of the Holders'
securities in such underwriting unless they accept the terms of the
underwriting as agreed upon between the Company and the underwriters
selected by it (or by other persons entitled to select the underwriters),
and then only in such quantity as the underwriters determine in their sole
discretion will not jeopardize the success of the offering by the Company.
(iii) Demand Registration. If the registration referred to in
paragraph C(i) is being made by the Company to satisfy demand registration
rights (a "Demand Registration") held by any person or entity (a "Demanding
Holder"), the Company shall not be required under paragraph C(i) to include
any of the Holders' securities in such registration, except in such
quantity as the Demanding Holder shall determine in its sole discretion,
subject to the provisions of paragraph C(iv) below.
-3-
(iv) Cutbacks. If the total amount of securities, including
Registrable Securities, requested by stockholders to be included in an
underwritten offering or a Demand Registration exceeds the amount of
securities sold other than by the Company or the Demanding Holder,
respectively, that the underwriters or Demanding Holder, respectively,
determine in their sole discretion is compatible with the success of the
offering, then the Company shall be required to include in the offering
only that number of such securities, including Registrable Securities,
which the underwriters or Demanding Holder, respectively, determine in
their sole discretion will not jeopardize the success of the offering (the
securities so included to be apportioned pro rata (to the nearest 100
shares) among the selling stockholders according to the total amount of
securities entitled to be included therein owned by each selling
stockholder or in such other proportions as shall mutually be agreed to by
such selling stockholders). For purposes of the preceding apportionment,
for any participating Holder that is a partnership, limited liability
company or corporation, the partners, retired partners, members, retired
members and stockholders of such Holder, or the estates and family members
of any such partners, members, retired partners or members and any trusts
for the benefit of any of the foregoing persons shall be deemed to be a
single "selling stockholder," and any pro-rata reduction with respect to
such "selling stockholder" shall be based upon the aggregate amount of
shares carrying registration rights owned by all Persons included in such
"selling stockholder," as defined in this sentence.
(v) Right to Terminate Registration. The Company shall have the right
to terminate or withdraw any registration initiated by it under this
subsection C prior to the effectiveness of such registration whether or not
any Holder has elected to include Registrable Securities in such
registration.
(vi) No request pursuant to this Section 3C may be made after August
30, 2008.
D. OBLIGATIONS OF THE COMPANY. Whenever required under this Section 3 to
effect the registration of any Registrable Securities, the Company shall, as
expeditiously as reasonably possible:
(i) Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause
such registration statement to become effective.
(ii) Prepare and file with the SEC such amendments and supplements to
such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of
the Securities Act.
(iii) Furnish to the Holders such numbers of copies of a prospectus,
including a preliminary prospectus, in conformity with the requirements of
the Securities Act, and such other documents as they may reasonably request
in order to facilitate the disposition of such Registrable Securities.
-4-
(iv) Use its reasonable best efforts to register and qualify the
securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by the Holders, provided that the Company shall not be required
in connection therewith or as a condition thereto to qualify to do business
or to file a general consent to service of process in any such states or
jurisdictions.
(v) In the event of any underwritten public offering, enter into and
perform its obligations under an underwriting agreement with the managing
underwriter of such offering in usual and customary form and consistent
with the other provisions of this Agreement. Each Holder participating in
such underwriting shall also enter into and perform its obligations under
such an agreement.
(vi) Promptly notify each Holder covered by the registration statement
at any time when the Company becomes aware of the happening of any event as
a result of which the registration statement or the prospectus included in
such registration statement or any supplement to the prospectus (as then in
effect) contains any untrue statement of a material fact or omits to state
a material fact necessary to make the statements there in (in the case of
the prospectus, in light of the circumstances under which they were made)
not misleading or, if for any other reason it shall be necessary during
such time period to amend or supplement the registration statement or the
prospectus in order to comply with the Securities Act, whereupon, in either
case, each Holder shall immediately cease to use such registration
statement or prospectus for any purpose and, as promptly as practicable
thereafter, the Company shall prepare and file with the SEC, and furnish
without charge to the appropriate Holders and managing underwriters, if
any, a supplement or amendment to such registration statement or prospectus
which will correct such statement or omission or effect such compliance and
such copies thereof as the Holders and any underwriters may reasonably
request.
(vii) Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange or market on which
similar securities issued by the Company are then listed or traded, if
applicable.
(viii) Provide a transfer agent and registrar for such Registrable
Securities not later than the effective date of such registration.
(ix) Use its reasonable best efforts to furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to this
Section 3, on the date that such Registrable Securities are delivered to
the underwriters for sale in connection with a registration pursuant to
this Section 3, if such securities are being sold through underwriters, or,
if such securities are not being sold through underwriters, on the date
that the registration statement with respect to such securities becomes
effective, (i) an opinion, dated such date, of the counsel representing the
Company for the purposes of such registration, in form and substance as is
customarily given to underwriters in an underwritten public offering,
addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities and (ii) a letter dated such date,
from the
-5-
independent certified public accountants of the Company, in form and
substance as is customarily given by independent certified public
accountants to underwriters in an underwritten public offering, addressed
to the underwriters, if any, and to the Holders requesting registration of
Registrable Securities (to the extent the then applicable standards of
professional conduct permit said letter to be addressed to the Holders).
E. FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 3 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities.
F. EXPENSES OF REGISTRATION. All expenses incurred in connection with a
registration requested pursuant to this Section 3, including (without
limitation) all registration, filing, qualification, printers' and accounting
fees and the reasonable fees and disbursements of one counsel for the selling
Holder or Holders selected by Holders selling a majority of the subject
Registrable Securities, such fees and disbursements not to exceed $10,000 for
each requested registration, and counsel for the Company shall be borne by the
Company, and any underwriters' discounts or commissions associated with
Registrable Securities shall be borne pro rata by the Holder or Holders
participating in the Form S-3 Registration.
G. INDEMNIFICATION. In the event any Registrable Securities are included in
a registration statement under this Section 3:
(i) The Company agrees to indemnify and hold harmless each Holder and
each person, if any, who (i) controls such Holder within the meaning of
Section 15 of the Securities Act or Section 20 of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), or (ii) is controlled by or
is under common control with a Holder from and against any and all losses,
claims, liabilities, expenses and damages (including, but not limited to,
any and all investigative, legal and other expenses reasonably incurred in
connection with, and any and all amounts paid in settlement of, any action,
suit or proceeding between any of the indemnified parties and any
indemnifying parties or between any indemnified party and any third party,
or otherwise, or any claim asserted), as and when incurred, to which the
Holder, or any such person, may become subject under the Securities Act,
the Exchange Act or other federal or state statutory law or regulation, at
common law or otherwise, insofar as such losses, claims, liabilities,
expenses or damages arise out of or are based, directly or indirectly, on
(x) any untrue statement or alleged untrue statement of a material fact
contained in any preliminary prospectus, registration statement or final
prospectus filed with the SEC pursuant to this Section 3, or any amendment
or supplement to any such registration statement or prospectus, or in any
application or other document executed by or on behalf of the Company or
based on written information furnished by or on behalf of the Company filed
in any jurisdiction in order to qualify the Registrable Securities under
the securities laws thereof or filed with the SEC, or (y) the omission or
alleged omission to state in such document a material fact required to be
stated in it or necessary to make the statements in
-6-
it not misleading; provided that this indemnity agreement shall not apply
to the extent that such loss, claim, liability, expense or damage is caused
directly by an untrue statement or omission made in reliance on and in
conformity with information relating to the Holder and furnished in writing
to the Company by the Holder expressly stating that such information is
intended for inclusion in any document described in clause (i)(x) above.
Any reference in this subsection G to a registration statement, prospectus
or any amendment or supplement thereto shall be deemed to refer to and
include any documents incorporated or deemed to be incorporated by
reference therein, and any reference to the terms "amend," "amendment" or
"supplement" with respect to such registration statement or prospectus
shall be deemed to refer to and include filing with the SEC of any document
incorporated or deemed to be incorporated by reference therein. This
indemnity agreement will be in addition to any liability that the Company
might otherwise have.
(ii) Each Holder agrees to indemnify and hold harmless the Company and
its directors and each officer of the Company who signed a registration
statement in which Registrable Securities are included, and each person, if
any, who (x) controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act or (y) is controlled by or
is under common control with Company against any and all loss, liability,
claim, damage and expense described in the indemnity contained in
subsection (i) of this subsection, as incurred, but only with respect to
untrue statements or omissions, or alleged untrue statements or omissions,
made in such registration statement (or any amendments thereto) or any
preliminary or final prospectus (or any amendment or supplement thereto) in
reliance upon and in conformity with written information and relating to
such Holder furnished to the Company by such Holder expressly stating that
such information is intended for use in such registration statement (or any
amendment thereto) or such preliminary or final prospectus (or any
amendment or supplement thereto).
(iii) Any party that proposes to assert the right to be indemnified
under this subsection G will, promptly after receipt of notice of
commencement of any action against such party in respect of which a claim
is to be made against an indemnifying party or parties under this
subsection G, notify each such indemnifying party of the commencement of
such action, enclosing a copy of all papers served, but the omission so to
notify such indemnifying party will not relieve the indemnifying party from
(x) any liability that it might have to any indemnified party otherwise
than under this subsection G and (y) any liability that it may have to any
indemnified party under the foregoing provision of this subsection G
unless, and only to the extent that, such omission results in the
forfeiture of substantive rights or defenses by the indemnifying party. If
any such action is brought against any indemnified party and it notifies
the indemnifying party of its commencement, the indemnifying party will be
entitled to participate in and, to the extent that it elects by delivering
written notice to the indemnified party promptly after receiving notice of
the commencement of the action from the indemnified party, jointly with any
other indemnifying party similarly notified, to assume the defense of the
action, with counsel reasonably satisfactory to the indemnified party, and
after notice from the indemnifying party to the indemnified party of its
election to assume the defense, the
-7-
indemnifying party will not be liable to the indemnified party for any
legal or other expenses except as provided below and except for the
reasonable costs of investigation subsequently incurred by the indemnified
party in connection with the defense. The indemnified party will have the
right to employ its own counsel in any such action, but the fees, expenses
and other charges of such counsel will be at the expense of such
indemnified party unless (w) the employment of counsel by the indemnified
party has been authorized in writing by the indemnifying party, (x) the
indemnified party has reasonably concluded (based on advice of counsel)
that there may be legal defenses available to it or other indemnified
parties that are different from or in addition to those available to the
indemnifying party, (y) a conflict or potential conflict exists (based on
advice of counsel to the indemnified party) between the indemnified party
and the indemnifying party (in which case the indemnifying party will not
have the right to direct the defense of such action on behalf of the
indemnified party) or (z) the indemnifying party has not in fact employed
counsel to assume the defense of such action within a reasonable time after
receiving notice of the commencement of the action, in each of which cases
the reasonable fees, disbursements and other charges of counsel will be at
the expense of the indemnifying party or parties. It is understood that the
indemnifying party or parties shall not, in connection with any proceeding
or related proceedings in the same jurisdiction, be liable for the
reasonable fees, disbursements and other charges of more than one separate
firm admitted to practice in such jurisdiction at any one time for all such
indemnified party or parties. All such fees, disbursements and other
charges will be reimbursed by the indemnifying party promptly as they are
incurred. An indemnifying party will not be liable for any settlement of
any action or claim effected without its written consent. No indemnifying
party shall, without the prior written consent of each indemnified party,
settle or compromise or consent to the entry of any judgment in any pending
or threatened claim, action or proceeding relating to the matters
contemplated by this subsection G (whether or not any indemnified party is
a party thereto), unless such settlement, compromise or consent includes an
unconditional release of each indemnified party from all liability arising
or that may arise out of such claim, action or proceeding. Notwithstanding
any other provision of this subsection G, if at any time an indemnified
party shall have requested an indemnifying party to reimburse the
indemnified party for fees and expenses of counsel for which it is entitled
to reimbursement pursuant to this subsection G, such indemnifying party
agrees that it shall be liable for any settlement effected without its
written consent if (x) such settlement is entered into more than 45 days
after receipt by such indemnifying party of the aforesaid request, (y) such
indemnifying party shall have received notice of the terms of such
settlement at least 30 days prior to such settlement being entered into,
and (z) such indemnifying party shall not have reimbursed such indemnified
party in accordance with such request prior to the date of such settlement;
provided that an indemnifying party shall not be liable for any such
settlement effected without its consent if such indemnifying party, at
least five days prior to the date of such settlement, (x) reimburses such
indemnified party in accordance with such request for the amount of such
fees and expenses of counsel as the indemnifying party believes in good
faith to be reasonable and (y) provides written notice to the indemnified
party that the indemnifying party disputes in good faith the reasonableness
of the unpaid balance of such fees and expenses.
-8-
(iv) In order to provide for just and equitable contribution in
circumstances in which the indemnification provided for in the foregoing
paragraphs of this subsection G is applicable in accordance with its terms
but for any reason is held to be unavailable from the Company or any
Holder, the Company and the applicable Holders will contribute to the total
losses, claims, liabilities, expenses and damages (including any
investigative, legal and other expenses reasonably incurred in connection
with, and any amount paid in settlement of, any action, suit or proceeding
or any claim asserted, but after deducting any contribution received by the
Company from persons other than the applicable Holders, such as persons who
control the Company within the meaning of the Securities Act, officers of
the Company who signed the applicable registration statement and directors
of the Company, who also may be liable for contribution) to which the
Company and the applicable Holders may be subject in such proportion as
shall be appropriate to reflect the relative fault of the Company, on the
one hand, and the applicable Holders, on the other, with respect to the
statements or omission which resulted in such loss, claim, liability,
expense or damage, or action in respect thereof, as well as any other
relevant equitable considerations with respect to such offering. Such
relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or
omission or alleged omission to state a material fact relates to
information supplied by the Company or the applicable Holders, the intent
of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such statement or omission. The Company
and the Holders agree that it would not be just and equitable if
contributions pursuant to this subsection G(iv) were to be determined by
pro rata allocation or by any other method of allocation which does not
take into account the equitable considerations referred to herein. The
amount paid or payable by an indemnified party as a result of the loss,
claim, liability, expense, or damage, or action in respect thereof,
referred to above in this subsection G(iv) shall be deemed to include, for
the purpose of this subsection G(iv), any legal or other expenses
reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim to the extent
consistent with subsection G(iii) hereof. Notwithstanding the foregoing
provisions of this subsection G(iv), each Holder shall not be required to
contribute any amount in excess of the net proceeds received by it from the
offering and no person found guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) will be entitled to
contribution from any person who was not guilty of such fraudulent
misrepresentation. For purposes of this subsection G(iv), any person who
controls a party to this Agreement within the meaning of the Securities
Act, and any officers, directors, partners, employees or agents of a
Holder, will have the same rights to contribution as that party, and each
officer of the Company who signed the applicable registration statement
will have the same rights to contribution as the Company, subject in each
case to the provisions hereof. Any party entitled to contribution, promptly
after receipt of notice of commencement of any action against such party in
respect of which a claim for contribution may be made under this subsection
G(iv), will notify any such party or parties from whom contribution may be
sought, but the omission to so notify will not relieve that party or
parties from whom contribution may be sought from any other obligation it
or they may have under this subsection G(iv). Except for a settlement
entered into pursuant to the last sentence of subsection G(iii) hereof, no
party will be liable for contribution with respect to any action or claim
settled without its written consent if such consent is required pursuant to
subsection G(iii) hereof."
-9-
SCHEDULE 1
EXHIBIT A
NEITHER THESE SECURITIES NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE DISPOSED
OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE
SECURITIES ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND
IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THESE
SECURITIES AND THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE ARE
SUBJECT TO FURTHER RESTRICTIONS ON TRANSFER AS SET FORTH HEREIN.
NEOTHERAPEUTICS, INC.
WARRANT
No.______ Dated: ____________, 2001
NeoTherapeutics, Inc., a Delaware corporation (the "Company"), hereby
certifies that, for value received, Cantor ▇▇▇▇▇▇▇▇▇▇ & Co., or its registered
assigns ("Holder"), is entitled, subject to the terms set forth below, to
purchase from the Company up to a total of ________________ (________) shares of
Common Stock, $.001 par value per share (the "Common Stock"), of the Company
(each such share, a "Warrant Share" and all such shares, the "Warrant Shares")
at an exercise price equal to $_____ per share (as adjusted from time to time as
provided in Section 7, the "Exercise Price"), at any time and from time to time
from and after the date hereof and through and including ___________, 2006 (the
"Expiration Date"), and subject to the following terms and conditions:
1. Registration of Warrant. The Company shall register this Warrant upon
records to be maintained by the Company for that purpose (the "Warrant
Register"), in the name of the record Holder hereof from time to time. The
Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, and the Company shall not be affected by
notice to the contrary.
2. Registration of Transfers and Exchanges.
(a) This Warrant and the Warrant Shares shall not be sold,
transferred, assigned, pledged or hypothecated for a period of one year
following the issuance of this Warrant, except to a NASD Member participating in
the distribution contemplated by those certain Sales Agreements dated June 12,
2001 between the Company and Cantor ▇▇▇▇▇▇▇▇▇▇ & Co., and its bona fide officers
and/or partners, but not directors. This Warrant or the Warrant Shares issued
upon any exercise hereof may only be transferred (i) pursuant to an effective
registration statement under the Securities Act, (ii) to the Company or (iii)
pursuant to an
1
available exemption from, or in a transaction not subject to, the registration
requirements of the Securities Act. In connection with any transfer of this
Warrant or any Warrant Shares other than pursuant to an effective registration
statement or to the Company, the Company may require the transferor thereof to
provide to the Company an opinion of counsel to the transferor, the form and
substance of which opinion shall be reasonably satisfactory to the Company, to
the effect that such transfer may be made without registration under the
Securities Act. Holder agrees to the imprinting, so long as is required by
applicable securities laws, of a legend substantially similar to that first
above written on any New Warrant (as defined in Section 2(b) below). Any such
transferee shall agree by virtue of having a New Warrant registered in its name
in accordance with Section 2(b) below to be bound by the terms of this Warrant
and shall have the rights of Holder under this Warrant.
(b) The Company shall register the transfer of any portion of this
Warrant in conformance with Section 2(a) on the Warrant Register, upon surrender
of this Warrant, with the Form of Assignment attached hereto duly completed and
signed, to the Company at the office specified in or pursuant to Section 11.
Upon any such registration or transfer, a new warrant to purchase Common Stock,
in substantially the form of this Warrant (any such new warrant, a "New
Warrant"), evidencing the portion of this Warrant so transferred shall be issued
to the transferee and a New Warrant evidencing the remaining portion of this
Warrant not so transferred, if any, shall be issued to the transferring Holder.
The acceptance of the New Warrant by the transferee thereof shall be deemed the
acceptance of such transferee of all of the rights and obligations of a holder
of a Warrant.
(c) This Warrant is exchangeable, upon the surrender hereof by the
Holder to the office of the Company specified in or pursuant to Section 3(b),
for one or more New Warrants, evidencing in the aggregate the right to purchase
the number of Warrant Shares which may then be purchased hereunder.
3. Duration and Exercise of Warrant.
(a) This Warrant shall be exercisable by the then registered Holder on
any business day before 5:00 P.M., California time, at any time and from time to
time on or after the date hereof to and including the Expiration Date. At 5:00
P.M., California time on the Expiration Date, the portion of this Warrant not
exercised prior thereto shall be and become void and of no value.
(b) Subject to Sections 2(c), and 4, upon surrender of this Warrant,
with the Form of Election to Purchase attached hereto duly completed and signed,
to the Company at its address for notice set forth in Section 11 and upon
payment of the Exercise Price multiplied by the number of Warrant Shares that
the Holder intends to purchase hereunder, in the manner provided hereunder, all
as specified by the Holder in the Form of Election to Purchase, the Company
shall promptly, but in no event later than 3 business days after the applicable
Date of Exercise (as defined below), issue or cause to be issued and cause to be
delivered to or upon the written order of the Holder and in such name or names
as the Holder may designate, a certificate for the Warrant Shares issuable upon
such exercise, free of restrictive legends except as are required under
applicable securities laws. Any person so designated by the Holder to receive
Warrant Shares shall be deemed to have become the holder of record of such
Warrant Shares as of the Date of Exercise of this Warrant.
2
A "Date of Exercise" means the date on which the Company shall have
received (i) this Warrant (or any New Warrant, as applicable), with the Form of
Election to Purchase attached hereto (or attached to such New Warrant)
appropriately completed and duly signed, and (ii) payment, if applicable, of the
Exercise Price for the number of Warrant Shares so indicated by the holder
hereof to be purchased.
(c) This Warrant shall be exercisable, either in its entirety or, from
time to time, for a portion of the number of Warrant Shares. If less than all of
the Warrant Shares which may be purchased under this Warrant are exercised at
any time, the Company shall issue or cause to be issued, at its expense, a New
Warrant evidencing the right to purchase the remaining number of Warrant Shares
for which no exercise has been evidenced by this Warrant.
(d) Prior to the exercise of this Warrant, the Holder shall not be
entitled to any rights as a stockholder of the Company with respect to the
Warrant Shares, including (without limitation) the right to vote such shares,
receive dividends or other distributions thereon or be notified of stockholder
meetings (except as otherwise set forth in Section 7(g) herein).
4. Payment of Taxes. The Company will pay any documentary stamp taxes
attributable to the issuance of Warrant Shares upon the exercise of this
Warrant; provided, however, that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the registration
of any certificates for Warrant Shares or Warrants in a name other than that of
the Holder. The Holder shall be responsible for all other tax liability that may
arise as a result of holding or transferring this Warrant or receiving Warrant
Shares upon exercise hereof.
5. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or
destroyed, the Company shall issue or cause to be issued in exchange and
substitution for and upon cancellation hereof, or in lieu of and substitution
for this Warrant, a New Warrant, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and indemnity, if
requested, reasonably satisfactory to it. Applicants for a New Warrant under
such circumstances shall also comply with such other reasonable regulations and
procedures and pay such other reasonable charges as the Company may prescribe.
6. Reservation of Warrant Shares. The Company covenants that it will at all
times reserve and keep available out of the aggregate of its authorized but
unissued Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of this Warrant as herein provided, the number of Warrant
Shares which are then issuable and deliverable upon the exercise of this entire
Warrant, free from preemptive rights or any other actual contingent purchase
rights of persons other than the Holder (taking into account the adjustments and
restrictions of Section 7). The Company covenants that all Warrant Shares that
shall be so issuable and deliverable shall, upon issuance and the payment of the
applicable Exercise Price in accordance with the terms hereof, be duly and
validly authorized and issued, fully paid and nonassessable.
3
7. Certain Adjustments. The Exercise Price and number of Warrant Shares
issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this Section 7.
(a) If the Company, at any time while this Warrant is outstanding, (i)
shall pay a stock dividend (except scheduled dividends paid on outstanding
preferred stock as of the date hereof which contain a stated dividend rate) or
otherwise make a distribution or distributions on shares of its Common Stock or
on any other class of capital stock and not the Common Stock) payable in shares
of Common Stock, (ii) subdivide outstanding shares of Common Stock into a larger
number of shares, or (iii) combine outstanding shares of Common Stock into a
smaller number of shares, the Exercise Price shall be adjusted by multiplying
the Exercise Price in effect immediately before such event by a fraction of
which the numerator shall be the number of shares of Common Stock (excluding
treasury shares, if any) outstanding before such event and the denominator shall
be the number of shares of Common Stock (excluding treasury shares, if any)
outstanding after such event. The number of Warrant Shares issuable upon
exercise of this Warrant shall be adjusted upon such adjustment of the Exercise
Price by multiplying the number of Warrant Shares issuable upon exercise of this
Warrant immediately prior to such adjustment by a fraction of which the
denominator shall be the number of shares of Common Stock (excluding treasury
shares, if any) outstanding before such event and the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding
after such event. Any adjustment made pursuant to this Section 7(a) shall become
effective immediately after the record date for the determination of
stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision or
combination, and shall apply to successive subdivisions and combinations.
(b) In case of any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is converted into
other securities, cash or property, then the Holder shall have the right
thereafter to exercise this Warrant only into the shares of stock and other
securities and property receivable upon or deemed to be held by holders of
Common Stock following such reclassification or share exchange, and the Holder
shall be entitled upon such exercise to receive such amount of securities or
property equal to the amount of Warrant Shares such Holder would have been
entitled to had such Holder exercised this Warrant immediately prior to such
reclassification or share exchange. The terms of any such reclassification or
share exchange shall include such terms so as to continue to give to the Holder
the right to receive the securities or property set forth in this Section 7(b)
upon any exercise following any such reclassification or share exchange.
(c) In case of the closing of any (1) merger or consolidation of the
Company with or into another Person, or (2) sale by the Company of more than
one-half of the assets of the Company (on a book value basis) in one or a series
of related transactions, then the Holder shall have the right thereafter to
exercise this Warrant for the shares of stock and other securities, cash and
property receivable upon or deemed to be held by holders of Common Stock
following such merger, consolidation or sale, and the Holder shall be entitled
upon exercise of this Warrant to receive such amount of securities, cash and
property as the Common Stock for which this Warrant could have been exercised
immediately prior to such merger, consolidation or sale would have been
entitled. The terms of any such merger, consolidation or sale shall include such
terms so as continue to give the Holder the right to receive the securities,
cash and property set forth in this Section 7(c) upon any conversion or
redemption following such event. This provision shall similarly apply to
successive such events.
4
(d) For the purposes of this Section 7, the number of shares of Common
Stock outstanding at any time shall be deemed to include the aggregate maximum
number of shares of Common Stock deliverable upon exercise, conversion or
exchange, as applicable (assuming the satisfaction of any conditions to
exercisability, convertibility or exchangeability, as applicable, including,
without limitation, the passage of time), of any options to purchase or rights
to subscribe for Common Stock, securities by their terms convertible into or
exchangeable for Common Stock or options to purchase or rights to subscribe for
such convertible or exchangeable securities then outstanding.
(e) All calculations under this Section 7 shall be made to the nearest
cent or the nearest 1/100th of a share, as the case may be.
(f) If:
(i) the Company shall declare a dividend (or any other
distribution) on its Common Stock; or
(ii) the Company shall declare a special nonrecurring cash
dividend on or a redemption of its Common Stock; or
(iii) the Company shall authorize the granting to all holders of
the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any
rights; or
(iv) the approval of any stockholders of the Company shall be
required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the
Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is
converted into other securities, cash or property; or
(v) the Company shall authorize the voluntary dissolution,
liquidation or winding up of the affairs of the Company,
then the Company shall cause to be mailed to each Holder at such Holder's last
address as it shall appear upon the Warrant Register, at least 15 calendar days
prior to the applicable record or effective date hereinafter specified, a notice
stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to
be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or
close, and the date as of which it is expected that holders of Common Stock of
record shall be entitled to exchange their shares of Common Stock for
securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer, share exchange, dissolution, liquidation
or winding up; provided, however, that the failure to mail such notice or any
defect therein or in the mailing thereof shall not affect the validity of the
corporate action required to be specified in such notice.
5
8. Payment of Exercise Price. The Holder shall pay the Exercise Price in
one of the following manners:
(a) Cash Exercise. The Holder may deliver immediately available funds
by certified check or bank draft payable to the order of the Company or by wire
transfer to an account designated by the Company; or
(b) Cashless Exercise. If the Date of Exercise is more than one year
after the date of this Warrant, the Holder may surrender this Warrant to the
Company together with a notice of cashless exercise, in which event the Company
shall issue to the Holder the number of Warrant Shares determined as follows:
Y(A - B)
X = --------
A
where:
X = the number of Warrant Shares to be issued to the Holder.
Y = the number of Warrant Shares with respect to which this
Warrant is being exercised.
A = the average of the closing bid prices of the Common Stock
for the five (5) trading days immediately prior to (but not including)
the Date of Exercise.
B = the Exercise Price.
9. Fractional Shares. The Company shall not be required to issue or cause
to be issued fractional Warrant Shares on the exercise of this Warrant. The
number of full Warrant Shares which shall be issuable upon the exercise of this
Warrant shall be computed on the basis of the aggregate number of Warrant Shares
purchasable on exercise of this Warrant so presented. If any fraction of a
Warrant Share would, except for the provisions of this Section 9, be issuable on
the exercise of this Warrant, the Company shall pay an amount in cash equal to
the Exercise Price multiplied by such fraction.
10. Notices. Any and all notices or other communications or deliveries
hereunder shall be in writing and shall be deemed given and effective on the
earliest of (i) the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile telephone number specified in this
Section prior to 5:00 p.m. (California time) on a business day, (ii) the
business day after the date of transmission, if such notice or communication is
delivered via facsimile at the facsimile telephone number specified in this
Section later than 5:00 p.m. (California time) on any date and earlier than
11:59 p.m. (California time) on such date, (iii) the business day following the
date of mailing, if sent by nationally recognized overnight courier service, or
(iv) upon actual receipt by the party to whom such notice is required to be
given. The addresses for such communications shall be: (i) if to the Company, to
▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇,
▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇, Attention: Chief Financial Officer, or to facsimile no. (949)
788-6706, with a copy to ▇▇▇▇▇▇ & ▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, attention ▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq., or (ii) if to the
Holder, to the Holder at the address or facsimile number appearing on the
Warrant Register or such other address or facsimile number as the Holder may
provide to the Company in accordance with this Section 10.
11. Warrant Agent. The Company shall serve as warrant agent under this
Warrant. The Company may appoint a new warrant agent upon notice to the Holder
in accordance with Section 10. Any corporation into which the Company may be
merged or any corporation resulting from any consolidation to which the Company
shall be a party or any corporation to which the Company transfers substantially
all of its corporate assets shall be a successor warrant agent under this
Warrant without any further act. Any such successor warrant agent shall promptly
cause notice of its succession as warrant agent to be mailed (by first class
mail, postage prepaid) to the Holder at the Holder's last address as shown on
the Warrant Register.
12. Miscellaneous.
(a) This Warrant shall be binding on and inure to the benefit of the
parties hereto and their respective successors and permitted assigns. This
Warrant may be amended only in writing signed by the Company and the Holder and
their successors and assigns. Subject to Section 2(a) above, this Warrant may be
assigned by the Holder to any affiliate of the Holder.
(b) Subject to Section 12(a), above, nothing in this Warrant shall be
construed to give to any person or corporation other than the Company and the
Holder any legal or equitable right, remedy or cause under this Warrant. This
Warrant shall inure to the sole and exclusive benefit of the Company and the
Holder.
(c) This Warrant shall be governed by and construed and enforced in
accordance with the internal laws of the State of California, without regard to
the principles of conflicts of law thereof. The Company and the Holder hereby
irrevocably submit to the exclusive jurisdiction of the state and federal courts
sitting in Orange County, California, for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waive, and agree not to assert in
any suit, action or proceeding, any claim that it is not personally subject to
the jurisdiction of any such court, or that such suit, action or proceeding is
improper. Each of the Company and the Holder hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action
or proceeding by receiving a copy thereof sent to the Company at the address in
effect for notices to it under this instrument and agrees that such service
shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve
process in any manner permitted by law.
(d) The headings herein are for convenience only, do not constitute a
part of this Warrant and shall not be deemed to limit or affect any of the
provisions hereof.
(e) In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Warrant shall not in any way be affected
or impaired thereby and the parties will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable
substitute therefor, and upon so agreeing, shall incorporate such substitute
provision in this Warrant.
7
IN WITNESS WHEREOF, the Company has caused this Warrant to be duly
executed by its authorized officer as of the date first indicated above.
NEOTHERAPEUTICS, INC.
By:
-----------------------------
▇▇▇▇▇▇ ▇▇▇▇▇
Chief Financial Officer
8
FORM OF ELECTION TO PURCHASE
(To be executed by the Holder to exercise the right to purchase shares of Common
Stock under the foregoing Warrant)
To NeoTherapeutics, Inc.:
In accordance with the Warrant enclosed with this Form of Election to
Purchase, the undersigned hereby irrevocably elects to purchase _________ shares
of common stock ("Common Stock"), $.001 par value per share, of NeoTherapeutics,
Inc. and, if such Holder is not utilizing the Cashless Exercise provisions set
forth in the Warrant, encloses herewith either (i) $_______ in cash, certified
or official bank check or checks, or (ii) a Fedwire Funds Transfer reference
number for the wire transfer of $_______ in immediately available funds to:
Chase Manhattan Bank, N.Y.C.
Routing No.: 021 000 021
FBO: ▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇, Inc.
Account No. ▇▇▇-▇▇▇ ▇▇▇
FCC: NeoTherapeutics, Inc.
Account No. ▇▇▇-▇▇▇▇▇-▇▇ 103
which sum represents in either case the aggregate Exercise Price (as defined in
the Warrant) for the number of shares of Common Stock to which this Form of
Election to Purchase relates, together with any applicable taxes payable by the
undersigned pursuant to the Warrant.
The undersigned requests that certificates for the shares of Common Stock
issuable upon this exercise be issued in the name of
PLEASE INSERT SOCIAL SECURITY OR
TAX IDENTIFICATION NUMBER
----------------------------------
--------------------------------------------------------------------------------
(Please print name and address)
If the number of shares of Common Stock issuable upon this exercise shall
not be all of the shares of Common Stock which the undersigned is entitled to
purchase in accordance with the enclosed Warrant, the undersigned requests that
a New Warrant (as defined in the Warrant) evidencing the right to purchase the
shares of Common Stock not issuable pursuant to the exercise evidenced hereby be
issued in the name of and delivered to:
--------------------------------------------------------------------------------
(Please print name and address)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Dated: __________, ______ Name of Holder:
(Print)
---------------------------------
(By:)
-----------------------------------
(Name:)
(Title:)
(Signature must conform in all respects
to name of holder as specified on the
face of the Warrant)
FORM OF ASSIGNMENT
[To be completed and signed only upon transfer of Warrant]
FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto ____________________ the right represented by the Warrant enclosed with
this Form of Assignment to purchase __________ shares of Common Stock of
NeoTherapeutics, Inc. to which the Warrant relates and appoints
____________________ attorney to transfer said right on the books of
NeoTherapeutics, Inc. with full power of substitution in the premises.
Dated: __________, ____
---------------------------------------
(Signature must conform in all respects
to name of holder as specified on the
face of the Warrant)
--------------------------------------
Address of Transferee
--------------------------------------
--------------------------------------
In the presence of:
--------------------------